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Abstract 
Background: To evaluate the clinical value of metabolic syndrome based on different definitions [American Heart 
Association/National Heart, Lung and Blood Institute (AHA/NHLBI), International Diabetes Federation (IDF) and Euro-
pean Group for the Study of Insulin Resistance (EGIR)] in middle-aged and elderly populations.
Methods: We studied 8643 participants from the Rotterdam study (1990–2012; mean age 62.7; 57.6 % female), a 
large prospective population-based study with predominantly elderly participants. We performed cox-proportional 
hazards models for different definitions, triads within definitions and each separate component for the risk of incident 
type 2 diabetes mellitus, coronary heart disease, stroke, cardiovascular- and all-cause mortality.
Results: In our population of 8643 subjects, metabolic syndrome was highly prevalent (prevalence between 19.4 and 
42.4 %). Metabolic syndrome in general was associated with incident type 2 diabetes mellitus (median follow-up of 
6.8 years, hazard ratios 3.13–3.78). The associations with coronary heart disease (median follow-up of 7.2 years, hazard 
ratios 1.08–1.32), stroke (median follow-up of 7.7 years, hazard ratios 0.98–1.32), cardiovascular mortality (median 
follow-up of 8.2 years, ratios 0.95–1.29) and all-cause mortality (median follow-up of 8.7 years, hazard ratios 1.05–1.10) 
were weaker. AHA/NHLBI- and IDF-definitions showed similar associations with clinical endpoints compared to the 
EGIR, which was only significantly associated with incident type 2 diabetes mellitus. All significant associations disap-
peared after correcting metabolic syndrome for its individual components.
Conclusions: Large variability exists between and within definitions of the metabolic syndrome with respect to risk 
of clinical events and mortality. In a relatively old population the metabolic syndrome did not show an additional pre-
dictive value on top of its individual components. So, besides as a manner of easy identification of high risk patients, 
the metabolic syndrome does not seem to add any predictive value for clinical practice.
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Background
The metabolic syndrome (MetS) is a combination of risk 
factors for type 2 diabetes mellitus and cardiovascular 
disease (CVD). Although MetS was designed to cluster 
and predict risk for type 2 diabetes mellitus and CVD, 
controversy remains on its usefulness in clinical practice. 
This is due to the fact that it is still not fully clear whether 
MetS has an added value to the prediction of diabetes, 
cardiovascular disease and mortality above the effect of 
its individual components [1–6].
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There are a number of different definitions according to 
which MetS can be defined which may have led to het-
erogeneity. The currently applied definitions have sub-
stantial differences in the predefined components and 
cut-off values [7–10]. Furthermore, most studies on the 
association between MetS and cardiovascular disease, 
mortality and diabetes have been performed in middle-
aged populations [11–15] while the associations of MetS 
with type 2 diabetes mellitus, CVD and mortality and the 
added value of MetS above its individual components in 
elderly populations has received less attention and has 
led to inconsistent results [2–5, 16–19].
Therefore the aim of our study was to determine 
the clinical value of MetS in a large prospective Dutch 
predominantly elderly population comparing three 
commonly applied definitions. We investigated the asso-
ciations of the definitions, their exact composition and 
the added predictive value above their individual compo-
nents with risk of type 2 diabetes mellitus, coronary heart 
disease (CHD), stroke, cardiovascular—and all-cause 
mortality.
Methods
Study population
Analyses were performed in the Rotterdam study, an 
ongoing prospective population-based cohort study in 
Rotterdam, The Netherlands. In 1989, all residents aged 
55 years or older in a well-defined district of Rotterdam 
were invited to participate in the original cohort (RS-
I). A total of 7983 (78.1  %) agreed to participate in the 
follow-up study. The study was extended in 2000 with a 
cohort of individuals who had reached age 55 or moved 
into the study area after the initial cohort (n = 3011). In 
2006, a third cohort of 3932 participants aged 45 years or 
older was enrolled, bringing the total study size to 14,926 
individuals. There were no eligibility criteria to enter the 
Rotterdam study cohorts except the minimum age and 
residential area. A more detailed description of the meth-
ods of the Rotterdam study can be found elsewhere [20, 
21].
Participants are being monitored for type 2 diabe-
tes mellitus, CHD, stroke and mortality by continuous 
linkage to files from general practitioners in the study 
area, information from medical specialists and dis-
charge reports after hospitalization. All information 
was obtained through trained research employees and 
reviewed by two independent medical doctors, super-
vised by a specialist in each separate medical field.
The Rotterdam study has been approved by the medi-
cal ethics committee according to the population study 
act Rotterdam study, executed by the Ministry of Health, 
Welfare and Sports of the Netherlands. Written informed 
consent was obtained from all participants.
Population for analysis
A total of 14,926 participants were included in three sub-
sequent cohorts in the Rotterdam study. From the first 
cohort entering the study in 1990 (n  =  7983) we used 
data from their third examination (n = 4797, 1997–1999) 
because of the availability of fasting blood samples. Fur-
thermore we used data from participants of the second 
(n  =  3011, 2000–2001) and third cohort (n  =  3932, 
2006–2008).
From the 11,740 participants mentioned above, 10,599 
went to the research center for blood sampling and 
anthropometric measurements. Only fasting participants 
were included in the study (n = 9819) Subsequently, we 
excluded 1176 prevalent cases of type 2 diabetes mel-
litus resulting in a population for analysis of n =  8643. 
For each given endpoint, prevalent cases of that endpoint 
where excluded. An average of 1.7  % had missing data 
on MetS-components. These were imputed by using the 
multiple imputation method described by Sterne et  al. 
[22].
Definitions of MetS
MetS was defined according to 3 definitions (Addi-
tional file  1: Table S1): (1) as stated by the American 
Heart Association/National Heart, Lung and Blood 
Institute (AHA/NHLBI) [8], which was later used with-
out adjustments in the consensus definition of IDF and 
AHA/NHLBI in 2009 [10], (2) according to the Interna-
tional Diabetes Federation (IDF) [9] and (3) according 
to the European Group for the Study of Insulin Resist-
ance (EGIR) [7]. A diagnosis of MetS according to AHA/
NHLBI-criteria consists of at least 3 of the following 
components: (1) waist circumference >102 cm for males 
or >88 cm for females; (2) HDL-cholesterol <1.03 mmol/l 
for males or HDL-cholesterol <1.29 mmol/l for females, 
(3) triglycerides  ≥1.7  mmol/l, (4) systolic blood pres-
sure ≥130 mmHg or diastolic blood pressure ≥85 mmHg 
or antihypertensive treatment; and (5) fasting glucose 
of ≥5.6 mmol/l or drug treatment for elevated glucose.
According to IDF-criteria, a diagnosis of MetS 
includes the component of central obesity (COB) as 
defined by waist circumference  ≥94  cm for males 
or waist circumference  ≥80  cm for females. If BMI 
is  >30  kg/m2, central obesity is assumed and waist 
circumference does not need to be measured. Cen-
tral obesity is the central component in the defini-
tion of MetS according to IDF. In addition to central 
obesity, two of the following four components should 
be present: (1) raised triglycerides  ≥1.7  mmol/l, (2) 
HDL-cholesterol  <1.03  mmol/l for males or HDL-
cholesterol  <1.29  mmol/l for females, (3) systolic 
blood pressure  ≥130  mmHg or diastolic blood pres-
sure  ≥85  mmHg or treatment of hypertension, (4) 
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raised fasting plasma glucose  ≥5.6  mmol/l or previ-
ously diagnosed type 2 diabetes mellitus. According 
to EGIR-criteria, the upper quartile of fasting insu-
lin in a non-diabetes population is required together 
with two of the following components: (1) hypergly-
cemia  ≥6.1  mmol/l but not having diabetes, (2) sys-
tolic blood pressure  ≥140  mmHg or diastolic blood 
pressure ≥90  mmHg or treatment of hypertension, (3) 
dyslipidemia as defined by triglycerides >2.0 mmol/l or 
HDL-C <1.0 mmol/l, (4) central obesity as defined by a 
waist circumference ≥94 cm for males or waist circum-
ference ≥80 cm for females.
Components and triads
According to the AHA/NHLBI-, IDF- and EGIR-criteria 
we defined MetS at baseline. Triads where defined as the 
simultaneous combination within a participant of any 
three different components of the MetS that would guar-
antee a diagnosis of MetS (a participant could have  >1 
triad at the same time).
Definition of type 2 diabetes mellitus
Incident type 2 diabetes mellitus was defined in accord-
ance with the guidelines of the American Diabetes Asso-
ciation [23, 24] and World Health Organization (WHO) 
[25] as a (1) fasting glucose level  ≥7.0  mmol/l or (2) a 
non-fasting glucose level  ≥11.1  mmol/l or (3) treat-
ment with oral glucose-lowering medication or insulin, 
and (4) diagnosis of diabetes as registered by a general 
practitioner or medical specialist. Prevalent cases of 
diabetes were diagnosed at baseline by a (1) non-fasting 
or post-load glucose level (after oral glucose tolerance 
test)  ≥11.1  mmol/l or (2) treatment with oral glucose-
lowering medication or insulin, and (3) diagnosis as reg-
istered by a general practitioner.
Definition of CHD
Incident CHD was defined as (1) myocardial revasculari-
zation (as a proxy for significant coronary artery disease), 
(2) Myocardial Infarction (MI, fatal and nonfatal) and (3) 
fatal CHD. Specific details on definitions in each catego-
ries in the Rotterdam study can be found elsewhere [26].
Definition of stroke
Stroke was defined according to WHO-criteria as a syn-
drome of rapidly developing clinical signs of focal (or 
global) disturbance of cerebral function, with symptoms 
lasting 24 h or longer or leading to death, with no appar-
ent cause other than of vascular origin [27]. History of 
stroke at baseline was assessed during the baseline inter-
view and verified by review of medical records. A more 
profound description on methods of data collection for 
stroke can be found elsewhere [28].
Definition of cardiovascular mortality and all‑cause 
mortality
Cardiovascular mortality was classified as mortality as a 
consequence of (1) CHD, (2) cerebrovascular disease, (3) 
atherosclerotic disease other than CHD or cerebrovascular 
disease (including ruptured abdominal aortic aneurysm, 
peripheral vascular disease, and visceral vascular disease) 
and (4) other cardiovascular disease. Specific details on 
definitions in each categories and methods of data collec-
tion of cardiac outcomes in the Rotterdam study can be 
found elsewhere [26]. With respect to all-cause mortality, 
information was obtained on a weekly basis from the cen-
tral registry of the municipality in Rotterdam and through 
general practitioners working in the study area.
Statistical analysis
Normally distributed continuous variables were 
expressed as mean ±  standard deviation (SD). Continu-
ous variables that were not normally distributed were 
log-transformed for the analysis and are expressed as a 
median with interquartile range. Age- and sex-adjusted 
logistic regression and Chi square tests were used to 
compare baseline characteristics of MetS and non-MetS 
participants. Cox proportional hazards models corrected 
for age, sex and ethnicity served to analyze the associated 
hazard ratio of MetS and incident type 2 diabetes mel-
litus, CHD, stroke, cardiovascular- and all-cause mor-
tality. All models were initially adjusted for age, sex and 
ethnicity. Ethnicity did not have a significant effect in 
any of the models and was therefore left out. To inves-
tigate whether the metabolic syndrome as a syndrome 
captures more of the risk for clinical endpoints than the 
individual components, we subsequently corrected the 
hazard ratios of MetS for each individual component. We 
imputed missing values by using the multiple imputation 
method, which has been proven to be a reliable method 
[22]. Participants with prevalent or unknown disease 
status were excluded from analyses on type 2 diabetes 
mellitus, CHD and stroke. Participants with prevalent or 
unknown stroke and/or CHD status were excluded from 
the analyses on cardiovascular mortality. For the analy-
sis on incident diabetes we performed sensitivity analyses 
in which we excluded participants with impaired fasting 
glucose levels (fasting glucose ≥5.6 mmol/l). All analyses 
were adjusted for age, sex and ethnicity. All analyses were 
performed with SPSS version 21.0 (SPSS, Chicago, IL, 
USA) and a 2-sided α smaller than 0.05 was used to claim 
statistical significance.
Results
Baseline characteristics
Baseline characteristics are shown in Table 1. The over-
all mean age at baseline was 62.7 years. Participants were 
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more often female (57.6 vs. 42.4 %). Between definitions, 
the mean age of the participants having MetS ranged 
from 64.2  years (AHA/NHLBI) to 62.1  years (EGIR). 
From our study population, 97.8  % were of Caucasian 
descent. Other baseline characteristics are being dis-
played in Table 1.
Prevalence of MetS
At baseline, a total of 4118 participants (47.6  %) were 
diagnosed with MetS according to either definition. The 
concordance of diagnoses using AHA/NHLBI, IDF and 
EGIR-definitions is displayed in Fig.  1. Thirty-five per-
cent had a diagnosis according to AHA/NHLBI, 42.2  % 
according to IDF, and 19.4 % according to EGIR (Table 2).
Prevalence of components and triads of MetS
Table 2 shows the prevalence of components and triads 
in each definition of MetS.
A combination of hyperglycemia, high blood pressure 
and central obesity was the most frequent triad within 
a diagnosis of MetS according to AHA/NHLBI and IDF. 
In the EGIR-definition, high blood pressure and central 
obesity together with hyperinsulinemia were most fre-
quently prevalent in MetS-diagnosed participants.
Risk of incident type 2 diabetes mellitus
During a median follow-up of 6.8  years 768 individuals 
developed type 2 diabetes mellitus. MetS was signifi-
cantly associated with the risk of type 2 diabetes mellitus 
regardless of the definition chosen (Table 3) in cox pro-
portional hazards models. Ethnicity did not have a sig-
nificant effect and was therefore left out of the model. 
The cox proportional hazard ratio (HR) was 3.78 (95  % 
CI 3.24–4.41) for AHA/NHLBI-definition, 3.53 (95 % CI 
3.01–4.14) for IDF definition, and 3.13 (95  % CI 2.69–
3.64) for EGIR-definition. The risk of type 2 diabetes mel-
litus was highly variable dependent on the composition of 
diagnosis (Additional file 1: Table S2). In MetS according 
to AHA/NHLBI, a combination of GLYC–HDL–WC (HR 
6.75; 95 % CI 5.53–8.25) was associated with the highest 
risk of type 2 diabetes mellitus. In MetS according to IDF, 
a combination of COB–HDL–GLYC (HR 6.07; 95  % CI 
5.01–7.35) was associated with the highest risk of type 2 
diabetes mellitus. For EGIR-diagnosis, the highest risk of 
type 2 diabetes mellitus was associated with a combina-
tion of INS–DYSL–GLYC (HR 7.35; 95 % CI 5.92–9.13). 
After correction for sex, age and individual components 
none of the MetS-definitions itself was significantly asso-
ciated with the risk of type 2 diabetes mellitus (Table 4). 
Table 1 Baseline characteristics of population diagnosed with MetS according to different definitions
Continuous data are mean ± SD when normally distributed. Otherwise median with interquartile range
AHA/NHLBI, American heart association/national heart, lung, and blood institute; IDF, International Diabetes Federation; EGIR, European Group for the Study of Insulin 
Resistance; MetS, metabolic syndrome; HDL, high-density lipoprotein; CRP, C-reactive protein; CHD, coronary heart disease
* Significant difference between MetS and non-MetS after correction for age and sex (P < 0.05)
Characteristic AHA/NHLBI IDF EGIR Total population
Participants having MetS (n, %) 3055 (35.3) 3646 (42.2) 1680 (19.4) 8643
Age, years 64.2 (58.8–72.5)* 64.0 (58.8–72.6)* 62.1 (57.1–70.8) 62.7 (57.6–71.2)
Female sex (n, %) 1790 (58.6) 2090 (57.3) 919 (54.7)* 4983 (57.7)
Body mass index (kg/m2) 29.3 ± 4.1* 28.9 ± 3.9* 30.3 ± 4.3* 27.0 ± 4.1
Waist-circumference, cm 100.0 ± 10.8* 98.9 ± 10.5* 102.0 ± 11.2* 92.8 ± 11.8
Systolic blood pressure, mmHg 145.6 ± 19.0* 145.3 ± 19.1* 144.1 ± 18.9* 138.3 ± 20.8
Diastolic blood pressure, mmHg 81.4 ± 11.4* 81.3 ± 11.4* 82.6 ± 11.7* 78.8 ± 11.4
Total cholesterol, mmol/l 5.8 ± 1.1* 5.8 ± 1.1* 5.7 ± 1.1 5.8 ± 1.0
HDL cholesterol, mmol/l 1.2 (1.0–1.4)* 1.2 (1.0–1.4)* 1.2 (1.0–1.4)* 1.4 (1.1–1.7)
Triglycerides, mmol/l 1.8 (1.4–2.3)* 1.7 (1.3–2.2)* 1.8 (1.3–2.4)* 1.3 (1.0–1.8)
Insulin, pmol/L 92 (67–129)* 88 (64–123)* 131 (111–166)* 69 (49–97)
Glucose, mg/L 5.8 (5.4–6.1)* 5.7 (4.5–6.1)* 5.8 (5.4–6.2)* 5.4 (1.1–1.7)
CRP, mg/mL 2.2 (1.0–4.4)* 2.0 (0.9–4.1)* 2.2 (1.0–4.6)* 1.5 (0.6–3.3)
Hypertension treatment (n, %) 1045 (34.2)* 1197 (32.8)* 92 (41.2)* 1873 (21.7)
Antidiabetic treatment (n, %) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Lipid treatment (n, %) 563 (18.4)* 630 (17.3)* 353 (21.0)* 1255 (14.5)
Current smoking (n,  %) 287 (9.4) 329 (9.0)* 114 (6.8)* 813 (9.4)
Caucasian descent (n, %) 2732 (98.2) 3255 (98.1) 1482 (96.9) 7655 (97.8)
Prevalent type 2 diabetes (n, %) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0 %)
Prevalent CHD (n, %) 218 (7.1)* 249 (6.8)* 121 (7.2)* 518 (6.0)
Prevalent Stroke (n, %) 95 (3.1)* 107 (3.0)* 54 (3.2)* 196 (2.3)
Page 5 of 10van Herpt et al. Cardiovasc Diabetol  (2016) 15:69 
The results were similar in a sensitivity analysis in which 
all participants with impaired fasting glucose levels (fast-
ing glucose  ≥5.6  mmol/l) were excluded from the cox 
regression modelling (Additional file 1: Table S7).
Risk of incident CHD
During a median follow-up of 7.2  years in which 544 
individuals developed CHD, MetS as defined by AHA/
NHLBI (HR 1.32; 95 % CI 1.11–1.56) and IDF (HR 1.38; 
95 % CI 1.16–1.63 P < 0.001) were significantly associated 
with the risk of CHD (Table  3). In our population, the 
EGIR definition was not associated with the risk of inci-
dent CHD. In MetS according to AHA/NHLBI, a com-
bination of BP–TRIG–WC (HR 1.77; 95 % CI 1.41–2.23) 
was associated with the highest risk of CHD (Additional 
file  1: Table S3). In MetS according to IDF, a combina-
tion of COB–TRIG–BP (HR 1.76; 95  % CI 1.44–2.15) 
was associated with the highest risk of CHD. For EGIR-
diagnosis, the highest risk of CHD was associated with a 
combination of INS–BP–DYSL (HR 1.26; 95 % CI 0.29–
1.72). After correction for age, sex and individual com-
ponents none of the MetS-definitions were significantly 
associated with CHD (Table 4).
Risk of incident stroke
During a median follow-up of 7.7  years in which 458 
participants suffered from incident stroke, MetS accord-
ing to AHA/NHLBI (HR 1.29; 95  % CI 1.07–1.56) and 
IDF (HR 1.32; 95 % CI 1.10–1.59) showed a significantly 
increased risk of stroke (Table  3). No association of the 
EGIR definition and incident stroke was found. In MetS 
according to AHA/NHLBI, a combination of GLYC–
HDL–WC (HR 1.75; 95 % CI 1.31–2.34) was associated 
with the highest risk of stroke (Additional file  1: Table 
S4). In MetS according to IDF, a combination of COB–
HDL–GLYC (HR 1.62; 95 % CI 1.26–2.10) was associated 
with the highest risk of stroke. For EGIR-diagnosis, the 
highest risk of stroke was associated with a combination 
of INS–BP–DYSL (HR 1.02; 95  % CI 0.70–1.49). After 
correction for age, sex and individual components none 
of the MetS-definitions were significantly associated with 
stroke (Table 4).
Fig. 1 Concordance and disparity in diagnosis of metabolic syn-
drome according to different definitions
Table 2 Prevalence of components/triads at RS-I-3 within diagnosis of MetS
AHA/NHLBI, American heart association/national heart, lung, and blood institute; IDF, International Diabetes Federation; EGIR, European Group for the study of Insulin 
Resistance; GLYC, hyperglycemia; BP, hypertension; TRIG, hypertriglyceridemia; HDL, low HDL-cholesterol; WC, increased waist circumference; COB, central obesity; 
DYSL dyslipidemia; INS, highest quartile of fasting insulin not having type 2 diabetes
AHA/NHLBI IDF EGIR
Metabolic Syndrome 3055 (35.3 %) 3646 (42.2 %) 1680 (19.4 %)
Components within diagnosis BP 2810 (92.0 %) COB 3646 (100 %) INS 1680 (100 %)
WC 2319 (75.9 %) BP 3302 (90.6 %) WC 1627 (96.8 %)
GLYC 2140 (70.0 %) GLYC 2489 (68.3 %) BP 1347 (80.2 %)
HDL 1688 (55.3 %) HDL 1750 (48.0 %) DYSL 864 (51.4 %)
TRIG 1849 (60.5 %) TRIG 1896 (52.0 %) GLYC 577 (34.3 %)
Triads within diagnosis GLYC-BP-WC 1469 (48.1 %) COB-GLYC-BP 2265 (62.1 %) INS-WC-BP 1302 (77.5 %)
BP-TRIG-WC 1075 (35.2 %) COB-HDL-BP 1474 (40.4 %) INS-WC-DYSL 821 (48.9 %)
GLYC-BP-TRIG 1004 (32.9 %) COB-TRIG-BP 1620 (44.4 %) INS-BP-DYSL 611 (36.4 %)
BP-HDL-WC 984 (32.2 %) COB-TRIG-HDL 1074 (29.5 %) INS-WC-GLYC 549 (32.7 %)
BP-TRIG-HDL 970 (31.8 %) COB-TRIG-GLYC 1067 (29.3 %) INS-BP-GLYC 431 (25.7 %)
GLYC-BP-HDL 838 (27.4 %) COB-HDL-GLYC 926 (25.4 %) INS-DYSL-GLYC 278 (16.5 %)
GLYC-TRIG-WC 728 (23.8 %)
TRIG-HDL-WC 710 (23.2 %)
GLYC-HDL-WC 627 (20.5 %)
GLYC-TRIG-HDL 633 (20.7 %)
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Risk of cardiovascular mortality
During a median follow-up of 8.2  years in which 418 
cardiovascular mortalities occurred, only the IDF-diag-
nosis was associated with significantly increased risk of 
cardiovascular mortality (HR 1.29; 95  % CI 1.05–1.57; 
P = 0.01) (Table 3). Within each definition, a large vari-
ability in hazard ratios for cardiovascular mortality was 
found (Additional file 1: Table S5). In MetS according to 
AHA/NHLBI, a combination of BP–TRIG–WC [HR 1.48 
(95 % CI 1.13–1.94)] was associated with the highest risk 
of cardiovascular mortality. In MetS according to IDF, a 
combination of COB-TRIG-BP (HR 1.45 (95 % CI 1.13–
1.85)) was associated with the highest risk of cardiovas-
cular mortality. Neither the EGIR diagnosis nor its triads 
were significantly associated with cardiovascular mortal-
ity. After adjustments for age, sex and individual com-
ponents none of the MetS definitions were significantly 
associated with cardiovascular mortality (Table 4).
Risk of all‑cause mortality
During a median follow-up of 8.7  years in which 2244 
participants deceased, MetS according to AHA/NHLBI 
(HR 1.10 (1.01–1.20) P = 0.03) and IDF (HR 1.09 (95 % 
CI 1.01–1.19) P  =  0.03) were associated with all-cause 
mortality. There was variability within definition as dis-
played by their triads (Additional file  1: Table S6). In 
MetS according to AHA/NHLBI, a combination of 
TRIG–HDL–WC (HR 1.24 (95  % CI 1.07–1.45)) was 
associated with the highest risk of all-cause mortality. In 
MetS according to IDF, a combination of COB–HDL–
GLYC (HR 1.18 (95 % CI 1.04–1.34)) was associated with 
the highest risk of all-cause mortality. After adjustments 
for age, sex and individual components none of the diag-
noses showed a significantly increased risk of all-cause 
mortality (Table 4).
Discussion
In our large predominantly elderly prospective popu-
lation-based study, we show there is large variability 
between and within the definitions of MetS with respect 
to prevalence- and risk estimates for important cardio-
vascular and metabolic clinical endpoints. In addition, 
we confirm that MetS does not have an additional value 
in the risk estimation of type 2 diabetes mellitus, CHD, 
stroke and mortality on top of its individual components.
MetS is a highly prevalent condition in our Dutch pop-
ulation. This is in line with previous reports on MetS in 
middle-aged and elderly populations in the United States 
and Europe that reported equal or higher prevalence esti-
mates [29–31]. We diagnosed the MetS according to the 
definitions of AHA/NHLBI, IDF and EGIR. The IDF-defi-
nition diagnosed the largest proportion of our population 
with MetS, followed by AHA/NHLBI and EGIR respec-
tively, which is similar to previous studies [5, 32, 33]. 
This can be explained by the lower IDF cut-off points for 
waist circumference and BMI, resulting in more individ-
uals that meet the central obesity-criterium. The EGIR-
diagnosis selects an upper quartile of fasting insulin and 
excludes prevalent diabetes, resulting in a lower preva-
lence compared to the other definitions.
In our population, MetS is a strong risk factor for type 2 
diabetes mellitus regardless of the definition chosen. This 
has already been found by several study groups in pre-
dominantly middle aged populations of various ethnicities 
[12, 15, 34, 35]. Sattar et al. also confirmed this association 
in elderly, predominantly male subjects and subjects at risk 
for cardiovascular disease [19]. However, these studies were 
partly based on self-reported data and the associations were 
mostly the result of the hyperglycemic component rather 
than the diagnosis of MetS itself. Our findings are in line 
with this study, since the association of MetS with type 2 
diabetes mellitus disappears after correcting for its compo-
nents of which the hyperglycemic component constitutes 
the largest hazard. Our study, being population-based and 
with larger and meticulous follow-up, therefore adds to the 
evidence provided by previous studies that MetS does not 
confer additional risk of type 2 diabetes mellitus above the 
sum of its components, especially fasting glucose [15, 19].
Table 3 Metabolic syndrome and hazard ratios for incident clinical endpoints
Data are presented as hazard ratios with 95 % confidence intervals. All analysis corrected for age and sex
AHA/NHLBI, American heart association/national heart, lung, and blood institute; IDF, International Diabetes Federation; EGIR, European group for the study of Insulin 
Resistance
* Statistically significant
Outcome Events in population AHA/NHLBI IDF EGIR
Type 2 diabetes mellitus 765/8567 3.78 (3.24–4.41)* 3.53 (3.01–4.14)* 3.13 (2.69–3.64)*
Coronary heart disease 544/7864 1.32 (1.11–1.56)* 1.38 (1.16–1.63)* 1.08 (0.87–1.35)
Stroke 458/8304 1.29 (1.07–1.56)* 1.32 (1.10–1.59)* 0.98 (0.77–1.25)
Cardiovascular mortality 418/7724 1.21 (0.99–1.47) 1.29 (1.05–1.57)* 0.95 (0.73–1.23)
All-cause mortality 2244/8586 1.10 (1.01–1.20)* 1.09 (1.01–1.19)* 1.05 (0.94–1.17)
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MetS is a known risk factor for CVD in middle aged 
and elderly populations [13, 14, 19, 36]. We found a 
relatively weak association of MetS with CVD in con-
cordance with previous associations reported in litera-
ture [19]. Our study adds to previous studies including 
a large meta-analysis [14] that show that MetS does not 
show additive value to the risk associated with the sum 
of its individual components [1, 2, 4, 5, 36]. Previous 
studies did find an independent associative role of MetS 
[37] and higher hazard ratios for MetS and incident car-
diovascular events [38]. However, these studies were 
done in small numbers of patients at younger age having 
essential hypertension [37] or being suspected of hav-
ing coronary artery disease [38]. Therefore, those results 
may not be similar to our study, which is a population-
based study with predominantly elderly participants. For 
stroke in particular, Kotani et  al. found MetS to have a 
positive association with stroke in women in a retro-
spective cohort [39]. We found MetS to be associated 
with stroke in the general population, but the associa-
tion disappeared after correcting for the individual MetS 
components.
Although earlier studies on middle-aged younger indi-
viduals suggested otherwise [11, 13, 14, 40], we did not 
Table 4 MetS according to different diagnosis and hazard ratios for  incident clinical endpoints corrected for  individual 
components
Data are presented as hazard ratios with 95 % confidence intervals. All analysis corrected for age and sex
AHA/NHLBI, American heart association/national heart, lung, and blood institute; IDF, International Diabetes Federation; EGIR, European group for the study of Insulin 
Resistance; GLYC, hyperglycemia; BP, hypertension; TRIG, hypertriglyceridemia; HDL, low HDL-cholesterol; WC, increased waist circumference; COB, central obesity; 
DYSL, dyslipidemia; INS, highest quartile of fasting Insulin not having type 2 diabetes
* Statistically significant
AHA/NHLBI IDF EGIR
Type 2 diabetes mellitus MetS 1.19 (0.90–1.58) MetS 1.11 (0.82–1.49) MetS 0.91 (0.56–1.49)
GLYC 4.01 (3.30–4.87)* GLYC 4.20 (3.45–5.12)* GLYC 5.12 (4.38–5.98)*
HDL 1.48 (1.24–1.76)* HDL 1.52 (1.29–1.80)* DYSL 1.64 (1.40–1.92)*
WC 1.48 (1.23–1.78)* BP 1.34 (1.08–1.65)* WC 1.33 (1.08–1.64)*
BP 1.28 (1.04–1.58)* COB 1.33 (0.99–1.78) INSUL 1.54 (0.98–2.44)
TRIG 1.24 (1.04–1.49)* TRIG 1.32 (1.12–1.55)* BP 1.39 (1.18–1.64)*
Coronary heart disease MetS 0.73 (0.53–1.01) MetS 1.18 (0.86–1.58) MetS 1.00 (0.55–1.81)
BP 1.67 (1.31–2.14)* BP 1.53 (1.20–1.95)* BP 1.50 (1.23–1.82)*
TRIG 1.48 (1.18–1.85)* TRIG 1.29 (1.04–1.59)* DYSL 1.36 (1.12–1.67)*
WC 1.38 (1.11–1.71)* HDL 1.17 (0.95–1.44) WC 1.10 (0.90–1.35)
HDL 1.34 (1.07–1.68)* COB 0.99 (0.76–1.28) GLYC 0.93 (0.74–1.18)
GLYC 0.94 (0.77–1.15) GLYC 0.82 (0.67–1.01) INSUL 0.87 (0.50–1.52)
Stroke MetS 1.09 (0.76–1.58) MetS 1.12 (0.80–1.56) MetS 0.91 (0.46–1.77)
BP 1.44 (1.10–1.89)* BP 1.42 (1.08–1.86)* BP 1.44 (1.16–1.79)*
HDL 1.36 (1.06–1.75)* HDL 1.35 (1.07–1.71)* GLYC 1.22 (0.96–1.56)
WC 1.06 (0.83–1.34) COB 1.11 (0.83–1.48) WC 1.20 (0.95–1.52)
GLYC 0.98 (0.78–1.22) GLYC 0.96 (0.76–1.21) DYSL 1.11 (0.88–1.41)
TRIG 0.84 (0.65–1.10) TRIG 0.84 (0.66–1.08) INSUL 0.87 (0.47–1.61)
Cardiovascular mortality MetS 0.86 (0.58–1.27) MetS 1.06 (0.74–1.54) MetS 0.79 (0.40–1.57)
BP 1.47 (1.10–1.97)* BP 1.39 (1.04–1.86)* BP 1.35 (1.07–1.69)*
TRIG 1.24 (0.94–1.62) COB 1.21 (0.89–1.63) WC 1.30 (1.01–1.67)*
WC 1.21 (0.94–1.55) TRIG 1.14 (0.89–1.47) GLYC 1.14 (0.88–1.47)
HDL 1.13 (0.86–1.48) HDL 1.05 (0.81–1.35) DYSL 1.07 (0.84–1.37)
GLYC 1.00 (0.79–1.26) GLYC 0.92 (0.71–1.18) INS 1.00 (0.54–1.86)
All-cause mortality MetS 0.97 (0.82–1.14) MetS 0.98 (0.85–1.14) MetS 0.81 (0.62–1.05)
HDL 1.25 (1.11–1.41)* HDL 1.24 (1.11–1.39)* INSUL 1.18 (0.93–1.50)
BP 1.09 (0.97–1.22) BP 1.08 (0.97–1.22) DYSL 1.15 (1.03–1.27)*
WC 1.02 (0.92–1.13) COB 1.05 (0.93–1.18) GLYC 1.11 (0.99–1.24)
GLYC 1.00 (0.90–1.10) GLYC 0.99 (0.89–1.10) BP 1.10 (1.00–1.21)*
TRIG 0.97 (0.86–1.10) TRIG 0.96 (0.86–1.08) WC 1.04 (0.94–1.15)
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find any significant associations of MetS with all-cause 
mortality after correction for its individual components 
in any of the definitions. This could very well be an effect 
of the relatively higher age of our population making 
study subjects equally prone to decease due to causes 
other than cardiometabolic disease, thereby reducing the 
relative effect of MetS. Our findings on all-cause mortal-
ity are in line with results obtained from patients after 
coronary artery bypass grafting (CABG) in which sur-
vival of MetS patients without diabetes resembled their 
matched background population [41].
Remarkably dyslipidemia and blood pressure were the 
main contributing factors for cardiovascular disease and 
cardiovascular- and all-cause mortality effects of MetS. 
Although these are known as important independent risk 
factors for coronary heart disease and atherosclerosis 
[42–47], this finding adds to the evidence that these indi-
vidual components important predictors in CVD [19].
The strengths of this study are the large sample size, pop-
ulation-based design and the long-term follow-up. Further-
more, data extraction has been done in a systematic way.
Despite the fact that we have executed this study with 
great care, we have to address some limitations of our 
study. Participants included in the Rotterdam study were 
mainly European Caucasians (97.8  %). Therefore our 
results may not apply to other ethnic groups. Consider-
ing the dynamic changes in European demographic, our 
results should be interpreted accordingly. Unfortunately 
a small proportion (1.7  %) of our population had miss-
ing data for the definition of MetS. We addressed this by 
applying a reliable multiple imputation method.
In this study, we approach the MetS as a predictive 
tool to identify patients at high risk for cardiometabolic 
endpoints. However as Tenenbaum and Fisman empha-
sized [48], MetS is still an interesting biological feature 
of coexistence of components. Research directed at the 
underlying mechanisms of their coexistence could lead to 
important biological insights in underlying cardiometa-
bolic disease pathophysiology. These studies are beyond 
the scope of our current epidemiological approach for 
prediction purposes.
In conclusion, MetS shows high variability in its asso-
ciation with clinical endpoints both within and between 
diagnoses according to different definitions. Also, in a 
relatively old population MetS did not have additional 
predictive value on top of its components for any of the 
cardiometabolic endpoints. Besides as a manner of easy 
identification of risk patients, MetS does not seem to add 
any predictive value for clinical practice.
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